Xeris Biopharma Holdings, Inc. (XERS) stock
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.80+0.10 (+0.60%)
Close on Nov 17, 2026Market cap $3.06BP/E –Yield –
Xeris Biopharma total assets
Total assets on the balance sheet at the end of each period.
Xeris Biopharma's total assets was $411.91M at Jun 30, 2026. For fiscal 2025 it was $383.53M, up 18.7% from the year before. The highest annual figure on record is $383.53M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $383.53M | +18.7% |
| FY2024 | Dec 31, 2024 | $323.06M | +0.1% |
| FY2023 | Dec 31, 2023 | $322.60M | -6.4% |
| FY2022 | Dec 31, 2022 | $344.52M | +13.2% |
| FY2021 | Dec 31, 2021 | $304.36M | +91.2% |
| FY2020 | Dec 31, 2020 | $159.15M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $411.91M | +23.1% |
| Q1 FY2026 | Mar 31, 2026 | $392.01M | +24.3% |
| Q4 FY2025 | Dec 31, 2025 | $383.53M | +18.7% |
| Q3 FY2025 | Sep 30, 2025 | $370.19M | +15.3% |
| Q2 FY2025 | Jun 30, 2025 | $334.69M | +0.9% |
| Q1 FY2025 | Mar 31, 2025 | $315.45M | -6.3% |
| Q4 FY2024 | Dec 31, 2024 | $323.06M | +0.1% |
| Q3 FY2024 | Sep 30, 2024 | $321.10M | -2.0% |
| Q2 FY2024 | Jun 30, 2024 | $331.73M | +0.9% |
| Q1 FY2024 | Mar 31, 2024 | $336.62M | +4.7% |
| Q4 FY2023 | Dec 31, 2023 | $322.60M | -6.4% |
| Q3 FY2023 | Sep 30, 2023 | $327.78M | +8.2% |
| Q2 FY2023 | Jun 30, 2023 | $328.78M | +3.2% |
| Q1 FY2023 | Mar 31, 2023 | $321.36M | -4.8% |
| Q4 FY2022 | Dec 31, 2022 | $344.52M | +13.2% |
| Q3 FY2022 | Sep 30, 2022 | $303.02M | +130.9% |
| Q2 FY2022 | Jun 30, 2022 | $318.62M | +100.2% |
| Q1 FY2022 | Mar 31, 2022 | $337.62M | – |
| Q4 FY2021 | Dec 31, 2021 | $304.36M | – |
| Q3 FY2021 | Sep 30, 2021 | $131.26M | – |
| Q4 FY2020 | Dec 31, 2020 | $159.15M | – |
See a number that looks wrong?